Search

A consensus paper by the Italian Sarcoma Group provides clinical recommendations for the treatment of localized angiosarcoma, a rare and aggressive vascular sarcoma. The paper highlights the unique challenges in managing angiosarcoma compared to other sarcomas and emphasizes the need for dedicated clinical recommendations. The Italian Sarcoma Group organized a consensus meeting to develop these recommendations, aiming to standardize and harmonize clinical practices for the optimal approach to localized angiosarcoma. The research concludes that further investigation through clinical trials is necessary to address uncertainties in the management of the disease. [Extracted from the article]

A recent paper published in iScience by an interdisciplinary team at MUSC Hollings Cancer Center explores the role of the bacteria Porphyromonas gingivalis in promoting drug resistance in oral cancer tumors. The researchers found that P. gingivalis interferes with chemotherapy-induced mitophagy, a process that removes damaged mitochondria, thereby allowing the tumors to become resistant to the drug's effects. The team identified the fimbriae, protein structures on the outside of the bacteria, as the key component responsible for this interference. The findings suggest that inhibiting the fimbriae with antibiotics could potentially prevent drug resistance. [Extracted from the article]

A research paper published in Oncotarget's Volume 15 on February 22, 2024, titled "Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas," explores the potential of combining sacituzumab govitecan (SG) with platinum-based chemotherapeutics in treating triple-negative breast cancer (TNBC), urinary bladder carcinoma (UBC), and small-cell lung carcinoma (SCLC). The study found that combining SG with carboplatin or cisplatin produced additive growth-inhibitory effects in vitro and significant antitumor effects in mice bearing TNBC, UBC, and SCLC tumors. The researchers suggest that further clinical investigation is warranted to explore the benefits of this combination therapy. [Extracted from the article]

A recent study from the University of Illinois Chicago suggests that a commonly used test to determine whether breast cancer patients should receive chemotherapy may be providing inaccurate recommendations for some Black women. The test, known as the 21-gene breast recurrence score, helps identify which tumors are more aggressive and therefore better candidates for chemotherapy. However, the study found that the test may underestimate the benefit of chemotherapy for Black women, leading them to forgo treatment when it could have been beneficial. The researchers recommend further study to determine if the test's cutoff point for recommending chemotherapy for Black women should be adjusted. The study also highlights the need to consider biological differences in tumors between racial and ethnic groups, while acknowledging the role of social factors and structural racism in healthcare disparities. [Extracted from the article]

A new editorial paper published in Oncoscience discusses the potential of antibody-drug conjugates (ADCs) in the treatment of gynecologic cancers. The researchers from Yale University School of Medicine highlight the challenges posed by aggressive subtypes of endometrial cancer and the high mortality rate associated with them. They emphasize the importance of cytoreductive surgery and chemotherapy in treatment, but also note the common recurrence of the disease. The researchers explore the use of immunotherapy in combination with chemotherapy and targeted drugs, specifically evaluating the efficacy of trastuzumab-deruxtecan (T-DXd) in treating biologically aggressive uterine tumors. [Extracted from the article]

A recent study conducted by the Polish Academy of Sciences has proposed a new method for quantitatively determining the concentration of the drug Metopimazine (MPZ) using spectrophotometry. MPZ is a dopamine antagonist used to treat nausea and vomiting, including those associated with cancer chemotherapy. The method involves measuring the absorbance of the drug's sulfoxide derivative and is specific for intact MPZ in the presence of decomposition products and excipients. The research demonstrated the possibility of quantitatively determining MPZ content in bulk drugs and tablets with a low relative standard deviation. [Extracted from the article]

A recent study published in JAMA Network Open by an international group of researchers examines the effectiveness of chemotherapy, with or without radiation therapy, before surgery for pancreatic cancer patients. The study focuses on pancreatic adenocarcinoma patients and found that nearly five percent of patients achieved a pathological complete response (pCR), meaning no detectable cancer cells were left in the area where the tumor was. Patients with pCR had a 5-year survival rate of 63 percent, compared to 30 percent for those without pCR. The study also explores factors that contribute to pCR and suggests tailoring treatment based on these factors could be beneficial. However, further research is needed to validate these findings and understand their broader applicability. [Extracted from the article]

A recent study from the Birla Institute of Technology and Science Pilani in Telangana, India, explores the advancements in nanotechnology-mediated platinum-based cancer therapy. Platinum-based drugs have been effective in cancer treatment, but their therapeutic usefulness is compromised by adverse effects and drug resistance. To overcome these limitations, researchers have focused on developing nanoparticle-mediated drug delivery systems for platinum-based drugs. This paper summarizes the structure and mechanisms of platinum compounds, various delivery systems for platinum drugs, and the potential of nanotechnology-enabled platinum-based cancer therapies. The study aims to assist researchers in developing innovative nanomedicine for anticancer applications. [Extracted from the article]

A recent study conducted by researchers at Huazhong University of Science and Technology in Wuhan, China, aimed to evaluate the efficacy and side effects of applying a second course of radiotherapy alone or in combination with chemotherapy for the treatment of recurrent esophageal cancer. The study analyzed data from 956 patients and found that combining the second course of radiotherapy with single-drug chemotherapy had advantages in treating recurrent esophageal cancer with manageable side effects. However, further subgroup analysis comparing the side effects of restorative radiation with combined chemotherapy using a single drug versus multiple drugs was not possible due to insufficient data. This research has been peer-reviewed and published in the Journal of X-Ray Science and Technology. [Extracted from the article]

A recent study conducted by researchers at Tufts University School of Medicine and Tufts Graduate School of Biomedical Sciences has shed light on how the chemotherapy drug doxorubicin can cause cardiac damage in some patients. The researchers found that the drug can induce a pro-inflammatory response in the heart, leading to chronic inflammation and fibrosis. They also discovered that CD8+ T-cells, a type of immune cell, play a role in this process. The findings suggest that blocking these T-cells from entering the heart could be a potential strategy to prevent cardiac damage associated with doxorubicin treatment. Further research will focus on understanding why the drug draws T-cells to attack cardiac tissue and exploring biomarkers that could predict cardiac damage. The study, which involved canine and human lymphoma patients, aims to develop safer treatment plans for cancer patients while protecting the heart. [Extracted from the article]

A study conducted by researchers at Guangxi University in Nanning, China, explores the challenges of chemotherapy optimization due to toxic side effects, drug resistance, and individual variations in cancers. The researchers propose a new algorithm called TA-MOSSA, which takes into account these factors to provide effective chemotherapy regimens for patients with different treatment approaches. The study emphasizes the importance of precise dosing to improve efficacy and reduce toxicity. The findings of this research can be found in the journal Applied Sciences. [Extracted from the article]

A recent study conducted by researchers at Tehran University of Medical Sciences explores the topic of chemotherapy-induced alopecia (CIA), a side effect that affects more than half of chemotherapy patients. The study highlights the significant psychosocial stress associated with CIA, including body image, self-esteem, and sexuality concerns. The researchers review various techniques used to prevent CIA, such as scalp compression, scalp cooling, and medical treatments. This article provides a concise overview of the study's findings and may be of interest to individuals researching alopecia and chemotherapy side effects. [Extracted from the article]

A recent study conducted by researchers at Northwestern University explores the evolution of therapy for locally advanced rectal cancer (LARC). The standard treatment for LARC involves preoperative chemoradiotherapy followed by surgery and adjuvant systemic chemotherapy. The study aims to determine the best sequence of treatments to improve survival, cure rate, and long-term toxicity profile. The research has been peer-reviewed and published in the Journal of Surgical Oncology. For more information, readers can contact Nicole J. Altomare at Northwestern University. [Extracted from the article]

A recent report from Universiti Malaya discusses research on cancer treatment using optimal control supported by swarm intelligence. The study aims to develop hybrid techniques that combine optimal control theory with evolutionary algorithms and multi-objective swarm algorithms to reduce cancerous cells while minimizing the use of chemotherapy medications and toxicity. Two hybrid techniques were proposed and evaluated, with MOEA/D emerging as the most effective algorithm in reducing tumor size and cancer drug concentration. The study highlights the importance of integrating optimal control theory and evolutionary algorithms for optimizing cancer chemotherapy treatment. [Extracted from the article]

A recent report from Huazhong University of Science and Technology in Wuhan, China, discusses the use of chemotherapy in pediatric cancer patients and its impact on pain and quality of life. The researchers conducted a bibliometric analysis of publications on this topic over the past decade and found an increasing trend in research. The United States had the highest number of publications, followed by China. The study highlights the need for more research on interventions to manage chemotherapy-induced pain in children and improve their quality of life. [Extracted from the article]

The article reports on the significant breakthrough announced by researchers at Children's Hospital of Philadelphia (CHOP) in understanding chemotherapy resistance in high-risk neuroblastoma. The findings were published in the journal "Cancer Discovery." Also mentioned are the high mortality rate of neuroblastoma and how neuroblastoma can evade chemotherapy according to the researchers.

A recent report from Watertown, New York discusses the use of personalized medicine in the treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer. The report highlights the potential of incorporating targeted agents like trastuzumab and immunotherapeutic agents like pembrolizumab into standard chemotherapy regimens to improve patient outcomes. Clinical trials have shown that adding trastuzumab and pembrolizumab to chemotherapy significantly improves progression-free and overall survival rates compared to chemotherapy alone. The integration of targeted and immunotherapeutic agents with traditional chemotherapy represents a shift towards more personalized and effective regimens in gastric cancer treatment. [Extracted from the article]

A study conducted by researchers at Mansoura University in Egypt aims to develop a machine learning-based approach to predict the response of neoadjuvant chemotherapy (NAC) in breast cancer patients. The proposed system analyzes multimodal magnetic resonance images along with clinical and molecular subtype markers to predict treatment outcomes. The system incorporates texture and functional radiomics from various MRI modalities and utilizes a leave-one-subject-out cross-validation approach. The results show that integrating clinical and molecular subtype markers with radiomics improves the efficiency of evaluating tumor response to NAC. [Extracted from the article]

The article focuses on research from Federal University of Ceara exploring the interaction between environmental factors, microbiota imbalance, and chemotherapy-induced intestinal mucositis. Topics include the role of microbiota in influencing drug response and toxicity, the bidirectional impact of chemotherapy on microbiota, and the potential of probiotics in mitigating chemotherapy side effects.

The article reports on new findings from Essex Partnership University Foundation Trust regarding the use of Clozapine in patients undergoing chemotherapy. Topics include the challenges of using Clozapine alongside myelosuppressive chemotherapy, the impact of Clozapine discontinuation on mental health stability, and the need for more evidence-based data on managing psychiatric and oncological treatments concurrently.

A recent study from the University of Michigan Health Rogel Cancer Center suggests that combining a fatty acid inhibitor with chemotherapy could enhance the effectiveness of treatment for patients with brain metastases from triple negative breast cancer. The research indicates that inhibiting fatty acid synthase, an enzyme that produces fatty acids, not only improves the efficacy of chemotherapy but also reduces the ability of cancer cells to spread. The study utilized new cell lines developed from a patient with brain metastases, providing a valuable resource for future research. While further investigation is needed, the findings offer promise for improving treatment outcomes in patients with triple-negative breast cancer. [Extracted from the article]

A new study conducted by researchers at the University of Texas Health Science Center in San Antonio explores the impact of exercise on cognitive function in cancer patients undergoing chemotherapy. The study reviewed 29 published articles that assessed cognitive function in adult cancer patients participating in exercise oncology trials. The findings suggest that there is a need for more standardized methods of evaluating cognitive function in these trials in order to better understand the role of exercise in preserving cognitive function. The study was published in Integrative Cancer Therapies. [Extracted from the article]

Researchers at the University of Baghdad have conducted a study on the impact of psychological scare and chemotherapy on the interaction between cancer and the immune system. The study proposes a mathematical model to explore how fear and chemotherapy affect the speed at which cancer cells multiply and the immune system's response. The researchers found that fear could contribute to the spread of tumors and weaken immune functionality. Numerical simulations were used to validate the study and determine the minimum therapy dosage needed to eradicate cancer in the presence of psychological distress. [Extracted from the article]

Researchers at Dalian Polytechnic University in Liaoning, China have developed a new approach to cancer treatment that targets cancer stem cells (CSCs). CSCs are resistant to conventional chemotherapy, so the researchers used hybrid nanoparticles to create a multi-dimensional control network. The nanoparticles, made of gold, silver, and organic drug components, were effective in killing cancer cells and CSCs, reducing their stemness and self-renewal capacity, and increasing their sensitivity to chemotherapy. This new thermo-chemotherapy platform shows promise in completely eliminating CSCs. [Extracted from the article]

Researchers at the Medical University of South Carolina (MUSC) Hollings Cancer Center have developed a new compound that shows promise in overcoming chemotherapy resistance in triple-negative breast cancer. The compound works by inhibiting the protein lysyl oxidase (LOX), which helps produce a "stiff" environment around tumors, preventing drug penetration. By using a LOX inhibitor, the structure of the tumor's extracellular matrix can be softened, allowing drugs to penetrate better. The compound has been tested in different models and has shown potential for treating other types of cancer as well. The researchers will continue to refine the compound and work towards obtaining Investigational New Drug (IND) status for clinical trials. [Extracted from the article]

A new report from Jagiellonian University in Krakow, Poland explores the potential of aclarubicin as a blockbuster drug in antitumor therapy. Aclarubicin is an anthracycline antibiotic with a multifaceted mechanism of antitumor activity. The research highlights the key mechanisms of action for aclarubicin, including its inhibition of topoisomerases, suppression of tumor invasion processes, generation of reactive oxygen species, and inhibition of angiogenesis. While aclarubicin has shown promise in clinical trials for acute myeloid and lymphoblastic leukemia, further research is needed to confirm its potential and explore combination therapies with other anticancer drugs. [Extracted from the article]

A recent study conducted by researchers at Henan University of Science and Technology in China explores the use of a novel tumor spheroid on a chip platform for drug screening in the treatment of esophageal cancer. The researchers developed inverse opal hydrogel scaffolds with tunable and organized pores, which allowed for the formation of uniform cell spheroids. These spheroids exhibited 3D growth patterns similar to those observed in vivo and showed increased sensitivity to chemotherapy agents compared to monolayer cells. The study suggests that this platform has potential for high-throughput tumor cell spheroid generation and drug screening, offering promise for chemotherapy drug development. [Extracted from the article]

A patent application has been submitted for a combination therapy to treat metastatic cancer. The inventor acknowledges that while combination chemotherapy has shown success in some cases, most common types of metastatic cancer remain incurable. The proposed therapy involves using redox cycling agents and bone marrow stem cell infusion to effectively treat metastatic cancers. The patent application discusses various methods for treating metastatic cancers, with a focus on achieving high rates of complete responses. Specific dosages and combinations of drugs are provided for different types of cancers and genetic mutations. [Extracted from the article]

A recent report from Haikou People's Hospital in China discusses the issue of drug resistance in cancer treatment. The researchers highlight that while chemotherapy is effective in delaying tumor growth, drug resistance remains a major obstacle to successful treatment. The study reviews the potential of natural active ingredients in reversing drug resistance and improving the efficiency of chemotherapy. The research emphasizes the complexity of drug resistance mechanisms and the need for further investigation in this area. [Extracted from the article]

This article discusses the use of immunotherapy in the treatment of colorectal cancer (CRC). Immunotherapy has shown promise as a first-line treatment for CRC patients with deficient mismatch repair (dMMR) and microsatellite instability-high (MSI-H) tumors, which have a higher response rate to immune checkpoint inhibitors (ICIs). Clinical trials have demonstrated favorable outcomes with immunotherapy compared to standard chemotherapy in these patients. However, immunotherapy has shown limited success in patients with microsatellite stable (MSS) CRC, which constitutes the majority of cases. Ongoing research aims to identify biomarkers and combination therapies to enhance the efficacy of immunotherapy in MSS CRC. Additionally, neoadjuvant and adjuvant therapies are being explored for early-stage CRC, and efforts are being made to identify reliable biomarkers to optimize immunotherapy. The future of CRC treatment lies in the integration of immunotherapy with traditional modalities and the development of personalized therapeutic strategies. [Extracted from the article]

A recent report from Oslo University Hospital in Norway discusses the use of retroperitoneal lymph node dissection (RPLND) as a treatment option for low-volume metastatic seminoma in testicular cancer patients. The study included 62 patients from Norway and Sweden who underwent RPLND surgery. The findings showed low complications and relapse rates, suggesting that RPLND could be an alternative to chemotherapy or radiation for selected patients with limited metastatic spread. This research provides valuable insights into the potential benefits of surgery as a treatment option for seminoma patients. [Extracted from the article]

A report from the Medical University of Silesia in Katowice, Poland discusses the challenges in treating pancreatic cancer. The five-year survival rates for this type of cancer are low, and the tumor's oligosymptomatic course and anatomical location make diagnosis difficult. Surgery and adjuvant chemotherapy are the main treatments for resectable cancer, while chemotherapy is the primary method for unresectable and metastatic cancers. The report suggests that radiotherapy, when combined with chemotherapy, could be a valuable method to improve treatment outcomes for pancreatic cancer. [Extracted from the article]

A report from the University of Brescia in Italy discusses the potential of radiomics, a noninvasive method that uses medical imaging to extract quantitative data from tumors, in predicting patient responsiveness to laryngeal preservation strategies for laryngeal cancer. The report highlights the promising results of studies that have used radiomics to assess the tumor and predict response to induction chemotherapy and radiation therapy. However, the report also emphasizes the need for larger multicentric studies to validate the value of radiomics in this field. The research concludes that while there are some early promising studies, the lack of validation and larger studies limits the application of radiomics in clinical practice. [Extracted from the article]

A study conducted by researchers at Warsaw University of Life Sciences in Poland has identified biomarkers that can be used to predict the prognosis of patients with triple-negative breast cancer (TNBC) who are eligible for neoadjuvant therapy. The study analyzed gene expression data from TNBC patients and classified them into two groups based on the presence or absence of certain gene markers. Patients with low expression of these markers had a favorable outcome, while those with high expression had a higher mortality rate. The study also found that breast cancer tumors undergo a transition to alternative subtypes after chemotherapy, highlighting the need for reevaluation of treatment strategies. [Extracted from the article]

A recent study conducted by NRG Oncology compared the outcomes of node-negative and node-positive pancreatic cancer patients when adding chemoradiation to systemic therapy. The trial data showed that the addition of radiation and chemotherapy improved overall survival (OS) for node-negative patients, but not for node-positive patients. Disease-free survival (DFS) was also improved with the addition of chemoradiation, driven by the improvement in node-negative patients. The study suggests that chemoradiation could be further tested in future adjuvant and neoadjuvant trials, and more research is needed to improve outcomes for node-positive patients. [Extracted from the article]

A recent study conducted by researchers at the University of Minnesota Twin Cities explores the use of chemotherapy as a treatment for cancer. The study proposes a new approach to controlling the growth of cancerous tumors by using artificial time-delayed theory. Unlike traditional methods, this approach does not rely on high-frequency switching or high gain, ensuring robustness without the need for extensive prior knowledge. Extensive simulation results support the efficacy of this proposed approach. For more information, the full article can be accessed through IEEE Access. [Extracted from the article]

A study conducted by researchers at Ningxia Medical University in Yinchuan, China, explores the potential use of histone deacetylase (HDAC) inhibitors as a therapy for chemotherapy-induced neuropathic pain. Chemotherapy drugs can cause damage to the spinal cord, brain, and peripheral nerve somatosensory neurons, leading to neuropathic pain. The study suggests that HDAC inhibitors may be a promising treatment for this type of pain and could improve the quality of life for patients. The research emphasizes the importance of identifying unique treatments for chemotherapy-induced neuropathic pain and developing combination therapies. [Extracted from the article]

Researchers from Xi'an Jiaotong-Liverpool University and other institutes in China have developed a molecule called dp53m, which targets a specific mutant version of the tumour protein P53 (TP53) called p53-R175H. This mutation is associated with lung, colorectal, and breast cancers, and can make tumours resistant to chemotherapy. The molecule, a proteolysis-targeting chimera (PROTAC), binds to the mutant protein and recruits an enzyme to break it down. Laboratory tests showed that dp53m inhibited the growth of cancer cells with the p53-R175H mutation, increased their sensitivity to chemotherapy, and did not harm healthy cells. This research suggests a potential therapeutic strategy for diseases associated with the p53-R175H mutation. [Extracted from the article]

A study conducted by researchers at Jiangnan University in Wuxi, China, has proposed a new method for assessing the efficacy of drugs in killing liver cancer cells. The study suggests the use of a microwave biosensor to detect the number of live cells and evaluate the effects of drug concentrations on cytotoxicity. The researchers compared the results obtained from the microwave biosensor with those from the CCK-8 method and found them to be congruent. This research supports the potential of microwave-based methods to quantify cell growth inhibition by drug concentrations. [Extracted from the article]

Researchers from Jiangsu University in China have conducted a study on the use of ferroptosis as a strategy for cancer therapy. Ferroptosis is a type of cell death that is triggered by intracellular iron and lipid peroxidation. The researchers found that inducing ferroptosis in cancer cells can inhibit their proliferation, migration, and invasion. Additionally, ferroptosis can affect the activity of immune cells in the tumor microenvironment, potentially regulating tumor immune escape. The study suggests that ferroptosis could be an effective strategy for cancer treatment, including chemotherapy, radiotherapy, and immunotherapy. [Extracted from the article]

MIT engineers have developed a closed-loop drug-delivery system that could improve chemotherapy by personalizing the dose to each patient. The current method of calculating chemotherapy doses based on body surface area does not take into account factors such as body composition, genetic makeup, and circadian fluctuations in drug-metabolizing enzymes. The new system, called CLAUDIA, continuously monitors drug concentrations in the patient's system and adjusts the infusion rate accordingly to keep the drug within the therapeutic window. In animal tests, CLAUDIA was able to keep drug levels within the target range for a longer period of time compared to traditional chemotherapy administration. [Extracted from the article]

Researchers from the Medical University of Lublin in Poland have presented new findings on esophageal cancer. The research highlights that over 600,000 new cases of esophageal cancer are registered worldwide each year. Treatment for the disease depends on the stage, with surgical treatment being the basis for early stages and radiochemotherapy or only radiochemotherapy being used for more advanced stages. Brachytherapy, a type of radiation therapy, can be used at any stage of the disease as both a radical and palliative treatment. The research also explores the role of combining brachytherapy with immunotherapy and the possibility of an abscopal effect. [Extracted from the article]

A study conducted by researchers from Tarbiat Modares University in Tehran, Iran, explores the effect of optimal chemotherapy doses on solid tumors during treatment and cancer recurrence after treatment. The researchers designed an optimal control problem and constructed three new optimal control problems by changing the control range, objective function, and adding a control. The study found that reducing the total dose of cytotoxic drugs during treatment leads to a rapid recurrence of cancer shortly after the end of treatment. The research has been peer-reviewed and published in Mathematical Methods in the Applied Sciences. [Extracted from the article]

A new study published in the Journal of American Medical Association suggests that individuals with early-stage triple-negative breast cancer (TNBC) who have high levels of immune cells within their tumors may have a lower risk of recurrence and better survival rates, even without chemotherapy. TNBC is a subtype of breast cancer that does not respond to certain drugs and is more likely to spread and recur. The study found that the abundance of immune cells, known as tumor-infiltrating lymphocytes (TILs), in breast tissue is a prognostic biomarker for TNBC. The findings may lead to future clinical trials exploring whether patients with high TILs can avoid intensive chemotherapy regimens. [Extracted from the article]

The results of a phase II clinical study on the use of the anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with chemotherapy as a first-line treatment for metastatic non-small cell lung cancer (NSCLC) were published in the journal Cell Reports Medicine. Lung cancer is a prevalent and deadly form of cancer, particularly in China. The study found that the combination treatment showed promising efficacy and tolerability, with a confirmed objective response rate of 46.0% and a median overall survival of 26.6 months. However, there were also treatment-related adverse events, including immune-related adverse events. Overall, the study suggests that KN046 combined with chemotherapy could be a promising treatment option for metastatic NSCLC. [Extracted from the article]

A new study from Guang'anmen Hospital in Beijing, China, explores the topic of arrhythmia, a common side effect of chemotherapy drugs. The study highlights the importance of addressing chemotherapy-related cardiotoxicity, which has become a leading cause of death after tumor recurrence. Traditional Chinese medicine is suggested as a potential intervention to reduce arrhythmic toxicity without compromising the anti-cancer effect of chemotherapy. The study provides an overview of the types and pathogenesis of chemotherapy-induced arrhythmia and summarizes the potential benefits of Chinese medicine compounds, combination formulas, and injections in the prevention and treatment of chemotherapy-induced arrhythmias. [Extracted from the article]

A study conducted at Taras Shevchenko National University of Kyiv in Ukraine has explored the potential of photocontrolled, biologically active compounds as drug candidates for cancer treatment. These compounds can be activated by non-ionizable light, providing a safer alternative to systemic chemotherapy. The study evaluated the potency and efficiency of these compounds in vitro and ex vivo, as well as their efficacy in vivo during early stages of drug development. The research utilized various cell cultures, tissue surrogates, and animal models to determine the most effective compounds and optimal light dosage. This study offers promising insights into the development of photopharmacology for cancer treatment. [Extracted from the article]

A recent study conducted at St. Vincent's University Hospital in Dublin, Ireland, examined the impact of a genetic test called the 21-Gene Recurrence Score (RS) on the treatment of invasive lobular early-stage breast carcinoma. The study found that RS testing resulted in a 75% reduction in chemotherapy use, leading to significant cost savings in the publicly funded health system. The research analyzed real-world data from a group of hormone receptor-positive, HER2-negative, lymph node-negative breast cancer patients and concluded that RS testing had a positive clinical and economic impact. [Extracted from the article]

A recent study conducted at the University of Pittsburgh explored the economic hardship experienced by women with early-stage breast cancer prior to or at their first chemotherapy treatment. The study found that factors such as race, area deprivation, perceived stress, symptom distress, and social support were associated with higher levels of economic hardship. Black patients, those living in areas of greater deprivation, and those with lower social support were more likely to experience economic hardship. The study highlights the importance of incorporating baseline holistic assessment to identify patients at risk of economic hardship during early-stage breast cancer treatment. [Extracted from the article]